- 10 min ago Grammys 2020: Billie Eilish Wins Big And Here Is A Look At Her Rebel Fashion Game
- 1 hr ago Hina Khan Looks Insanely Beautiful In Her Ivory Leaf-Patterns Sari
- 3 hrs ago Grammys 2020: Priyanka Chopra Jonas Impresses In A Satin Gown But Disappoints In A Sequin Kimono
- 5 hrs ago 9 Interesting Health Benefits Of Pecans
- Sports Martin Guptill swears at Yuzvendra Chahal in Hindi on live TV
- Finance Centre To Increase Deposit Insurance To Rs. 5 Lakh, Pay More On Bank Failure
- Movies Hrithik Roshan's Mother Pinkie Roshan Shakes A Leg To 'Ghungroo' Song At Sunaina's Birthday Bash
- News Explained: Who is this gynecologist from Ladakh who was awarded the Padma Bhushan
- Automobiles Tata Altroz Imaginator Launched: Five Options To Customize Your Altroz At The Factory
- Technology Poco X2 Possibly With Snapdragon 730g To Be Unveiled On February 4
- Travel 10 Most Popular Historical Places And Sites In Karnataka
- Education IIM Bangalore Women In Leadership Course Tanmatra
A study at University of Pittsburgh Cancer Institute (UPCI) has cited that the combination of two different biotherapies may turn out to be more beneficial for patients with inoperable melanoma.
The researchers used two biotherapies, treatments that stimulate the immune system to fight cancer, and found that the results were quite promising in terms of anti-tumor effects and tolerable in terms of toxicity.
It was the first time that the researchers combined two biotherapies in this phase 2 trial. The biotherapies were: High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body"s immune system.
“With each new study, we learn something important about melanoma. With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting," said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine.
In the study, the combination treatment was given to 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy
It was found that the overall response rate was 19 percent, and after that the study entered the second stage, where it will enroll 21 patients more.
Melanoma is a rare form of skin cancer, causing the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure.
In case of patients with inoperable disease, like those enrolled in this study, such discovery of a safe and effective treatment holds a big importance.
The study was presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.